TY - JOUR
T1 - Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation
AU - Kapelushnik, J.
AU - Nagler, A.
AU - Or, R.
AU - Naparstek, E.
AU - Ackerstein, A.
AU - Samuel, S.
AU - Morecki, S.
AU - Nabet, C.
AU - Slavin, S.
PY - 1996/12
Y1 - 1996/12
N2 - We describe a 17-year-old male patient with chronic myelogenous leukemia (CML) in hematologic and cytogenetic relapse 4 months post-non-T cell-depleted allogeneic bone marrow transplantation for accelerated CML. Two sequential buffy coat transfusions with donor peripheral blood cells (8.9 and 4.8 x 107 cells/kg), the second transfusion in combination with in vivo activation of donor cells by human recombinant interleukin-2 (rIL-2) 6 x 106 IU/m2 subcutaneously for 3 days, failed to induce remission. The patient responded to an infusion of donor peripheral blood lymphocytes (3.3 x 107 cells/kg) pre-activated in vitro with rIL-2 and additionally activated in vivo with rIL-2, 6 x 106 IU/m2/day subcutaneously for 3 days. Elimination of the Philadelphia (Ph) clone was confirmed by cytogenetic analysis showing a normal male karyotype and by disappearance of the bcr/abl transcript, using the polymerase chain reaction (PCR). At present, the patient is 26 months post-treatment with no evidence of disease, but with chronic graft-versus-host disease. Our data indicate that allogeneic activated cell therapy (allo-ACT) may provide antitumor effector cells that successfully induce graft-versus-leukemia (GVL) effects even when cell therapy with donor buffy coats was insufficient.
AB - We describe a 17-year-old male patient with chronic myelogenous leukemia (CML) in hematologic and cytogenetic relapse 4 months post-non-T cell-depleted allogeneic bone marrow transplantation for accelerated CML. Two sequential buffy coat transfusions with donor peripheral blood cells (8.9 and 4.8 x 107 cells/kg), the second transfusion in combination with in vivo activation of donor cells by human recombinant interleukin-2 (rIL-2) 6 x 106 IU/m2 subcutaneously for 3 days, failed to induce remission. The patient responded to an infusion of donor peripheral blood lymphocytes (3.3 x 107 cells/kg) pre-activated in vitro with rIL-2 and additionally activated in vivo with rIL-2, 6 x 106 IU/m2/day subcutaneously for 3 days. Elimination of the Philadelphia (Ph) clone was confirmed by cytogenetic analysis showing a normal male karyotype and by disappearance of the bcr/abl transcript, using the polymerase chain reaction (PCR). At present, the patient is 26 months post-treatment with no evidence of disease, but with chronic graft-versus-host disease. Our data indicate that allogeneic activated cell therapy (allo-ACT) may provide antitumor effector cells that successfully induce graft-versus-leukemia (GVL) effects even when cell therapy with donor buffy coats was insufficient.
KW - Activated allogeneic cell therapy
KW - BMT
KW - CML
UR - http://www.scopus.com/inward/record.url?scp=0030444337&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0030444337
VL - 18
SP - 1153
EP - 1156
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 6
ER -